Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2 1Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Oligodendroglioma 1Neoplasms 1Astrocytoma 1

Interventions

Cyclophosphamide 5Positron Emission Tomography Computed Tomography 4pembrolizumab 3Topotecan 2Surveys and Questionnaires 2Psilocybin 2Midazolam 2Methods 2Ketoconazole 2Ketamine 2temsirolimus 1posaconazole 1poly ICLC 1parathyroid hormone-related peptide (1-36) 1lavender oil 1jojoba wax 1ginger extract 1fluoromisonidazole 1fludarabine phosphate 1fludarabine 1fluciclovine F-18 1evolocumab 1etoposide phosphate 1beta-Glucans 1Whole-Body Irradiation 1Vincristine 1Varenicline 1Transplantation 1Transcranial Direct Current Stimulation 1Tetrahydrouridine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Neoplasms × Protein Subunit Vaccines × Clear all
NCT00874861 2015-12-08

HLA-A2-Restricted Glioma Antigen-Peptides Vaccinations With Poly-ICLC for Recurrent WHO Grade II Gliomas

University of Pittsburgh

Phase EARLY_PHASE1 Completed
10 enrolled
CNS

Astrocytoma, Neoplasms, Oligodendroglioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡